12:15 pm – 12:45 pm Registration and Lunch
12:45 pm – 12:50 pm Program Overview
12:50 pm – 1:00 pm Update on the Use of Biologics and Small Molecules for UC
1:00 pm – 1:10 pm Evaluation of Head-to-Head Clinical Trials
1:10 pm – 1:20 pm Real-World Experience
1:20 pm – 1:30 pm Putting It All Together
1:30 pm – 1:45 pm Closing Discussion and Question and Answer Session
Date / Time
Gary Lichtenstein, MD
Director, Center for Inflammatory Bowel Disease
Division of Gastroenterology
Department of Medicine
University of Pennsylvania School of Medicine
University of Pennsylvania Health System
Uma Mahadevan-Velayos, MD
Professor of Medicine
Department of Medicine, Division of Gastroenterology
University of California, San Francisco
San Francisco, California
The goal of this activity is to improve the competence of participants in weighing benefits vs risks of advanced UC therapies and to use these comparisons to make optimal treatment decisions for patients with moderate to severe UC.
This live program is intended for gastroenterologists and other clinicians who are attending the Crohn’s & Colitis Congress and other healthcare providers who care for patients with UC.
- Summarize emerging data from recent clinical trials that compared efficacy and safety of drugs from different biologic classes for the treatment of UC
- Describe real-world data for biologics therapies and how this information can provide insights on the use of specific agents in heterogeneous UC populations
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) by the American Gastroenterological Association. American Gastroenterological Association is accredited by the ACCME to provide continuing medical education for physicians.
American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Disclosure of Conflicts of Interest
AGA requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to AGA policy. AGA is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.